✦ LIBER ✦

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

✍ Scribed by Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janine L Mansi; Dharsha Shivapatham; Sami Shousha; Jie Jiang; David Peston; Nigel Barrett; David Vigushin; Ken Morrison; Emma Beresford; Simak Ali; Martin J Slade; R Charles Coombes

Book ID: 117783511
Publisher: The Lancet
Year: 2005
Tongue: English
Weight: 244 KB
Volume: 6
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(05)70176-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II neoadjuvant trial of anastroz

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

✍ Suleiman Massarweh; Yee L. Tham; Jian Huang; Krystal Sexton; Heidi Weiss; Anna T 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 361 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB